February 27, 2018 / 3:02 PM / 10 months ago

BRIEF-Endo Expects 2018 U.S. Generic Pharmaceuticals Revenue To Decline In The Mid-To High 30 Pct Range Versus Prior Year

Feb 27 (Reuters) - Endo International Plc:

* ENDO CFO SAYS ,"WE EXPECT 2018 U.S. GENERIC PHARMACEUTICALS REVENUE TO DECLINE IN THE MID- TO HIGH 30% RANGE VERSUS PRIOR YEAR" - CONF CALL

* ENDO CFO SAYS ,"U.S. BRANDED SPECIALTY AND ESTABLISHED PHARMACEUTICALS REVENUE IS EXPECTED TO DECLINE IN THE LOW TEENS VERSUS PRIOR YEAR" - CONF CALL

* ENDO CFO SAYS U.S. BRANDED STERILE INJECTABLES REVENUE IS EXPECTED TO GROW IN THE LOW DOUBLE-DIGIT PERCENTAGE RANGE VERSUS PRIOR YEAR - CONF CALL

* ENDO CFO SAYS INTERNATIONAL SEGMENT REVENUE IS EXPECTED TO DECLINE IN THE HIGH 40S PERCENTAGE RANGE - CONF CALL Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below